Ebenezer Daniel1, Wei Pan2, Gui-Shuang Ying2, Benjamin J Kim2, Juan E Grunwald2, Frederick L Ferris3, Glenn J Jaffe4, Cynthia A Toth4, Daniel F Martin5, Stuart L Fine6, Maureen G Maguire2. 1. Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: ebdaniel@mail.med.upenn.edu. 2. Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania. 3. National Eye Institute, Bethesda, Maryland. 4. Department of Ophthalmology, Duke University, Durham, North Carolina. 5. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. 6. Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colorado.
Abstract
PURPOSE: To describe risk factors for scar formation and changes to fibrotic scar through 5 years in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). DESIGN: Multicenter, prospective cohort study. PARTICIPANTS: A total of 1061 subjects in CATT. METHODS: Color photographic and fluorescein angiographic images from baseline and 1, 2, and 5 years were evaluated. Incidence of scar formation was estimated with Kaplan-Meier curves. Risk factors were assessed with Cox regression models. MAIN OUTCOME MEASURES: Scar formation, fibrotic scar area, and macular atrophy associated with fibrotic scar ("atrophy"). RESULTS: Cumulative proportion of eyes with scar was 32%, 46%, and 56% at years 1, 2, and 5, respectively. Baseline factors associated with increased risk (adjusted hazards ratio [aHR] and 95% confidence interval [CI]) were classic choroidal neovascularization (CNV) (aHR, 4.49; 95% CI, 3.34-6.04) versus occult, hemorrhage >1 disc area (DA) (aHR, 2.28; 95% CI, 1.49-3.47) versus no hemorrhage, retinal thickness >212 μm (aHR, 2.58; 95% CI, 1.69-3.94) versus <120 μm, subretinal tissue complex thickness >275 μm (aHR, 2.64; 95% CI, 1.81-3.84) versus ≤75 μm, subretinal fluid thickness >25 μm (aHR, 1.31; 95% CI, 0.97-1.75) versus no fluid, visual acuity (VA) in fellow eye 20/20 (aHR, 1.72; 95% CI, 1.25-2.36) versus 20/50 or worse, retinal pigment epithelium elevation absence (aHR, 1.71; 95% CI, 1.21-2.41), and subretinal hyperreflective material (aHR, 1.72; 95% CI, 1.25-2.36). Among 68 eyes that developed fibrotic scar at year 1, VA decreased by a mean of additional 13 letters between years 1 and 5. Mean scar area was 1.2, 1.2, and 1.9 DA at 1, 2, and 5 years, respectively. Atrophy was present in 18%, 24%, and 54% of these eyes at years 1, 2, and 5, respectively; the mean areas were 1.6, 2.0, and 3.1 DA, respectively. Atrophy replaced fibrotic scar in 8 eyes at year 5. There was no significant correlation between scar growth and atrophy growth. The rate of growth for both was similar between the clinical trial and observation periods. CONCLUSIONS: Several morphologic features, including classic CNV and large hemorrhage, are associated with scar formation. Rate of new scar formation declined after 2 years. Most fibrotic scars and accompanying macular atrophy expanded over time, reducing VA.
PURPOSE: To describe risk factors for scar formation and changes to fibrotic scar through 5 years in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). DESIGN: Multicenter, prospective cohort study. PARTICIPANTS: A total of 1061 subjects in CATT. METHODS: Color photographic and fluorescein angiographic images from baseline and 1, 2, and 5 years were evaluated. Incidence of scar formation was estimated with Kaplan-Meier curves. Risk factors were assessed with Cox regression models. MAIN OUTCOME MEASURES: Scar formation, fibrotic scar area, and macular atrophy associated with fibrotic scar ("atrophy"). RESULTS: Cumulative proportion of eyes with scar was 32%, 46%, and 56% at years 1, 2, and 5, respectively. Baseline factors associated with increased risk (adjusted hazards ratio [aHR] and 95% confidence interval [CI]) were classic choroidal neovascularization (CNV) (aHR, 4.49; 95% CI, 3.34-6.04) versus occult, hemorrhage >1 disc area (DA) (aHR, 2.28; 95% CI, 1.49-3.47) versus no hemorrhage, retinal thickness >212 μm (aHR, 2.58; 95% CI, 1.69-3.94) versus <120 μm, subretinal tissue complex thickness >275 μm (aHR, 2.64; 95% CI, 1.81-3.84) versus ≤75 μm, subretinal fluid thickness >25 μm (aHR, 1.31; 95% CI, 0.97-1.75) versus no fluid, visual acuity (VA) in fellow eye 20/20 (aHR, 1.72; 95% CI, 1.25-2.36) versus 20/50 or worse, retinal pigment epithelium elevation absence (aHR, 1.71; 95% CI, 1.21-2.41), and subretinal hyperreflective material (aHR, 1.72; 95% CI, 1.25-2.36). Among 68 eyes that developed fibrotic scar at year 1, VA decreased by a mean of additional 13 letters between years 1 and 5. Mean scar area was 1.2, 1.2, and 1.9 DA at 1, 2, and 5 years, respectively. Atrophy was present in 18%, 24%, and 54% of these eyes at years 1, 2, and 5, respectively; the mean areas were 1.6, 2.0, and 3.1 DA, respectively. Atrophy replaced fibrotic scar in 8 eyes at year 5. There was no significant correlation between scar growth and atrophy growth. The rate of growth for both was similar between the clinical trial and observation periods. CONCLUSIONS: Several morphologic features, including classic CNV and large hemorrhage, are associated with scar formation. Rate of new scar formation declined after 2 years. Most fibrotic scars and accompanying macular atrophy expanded over time, reducing VA.
Authors: Robert B Bhisitkul; Thais S Mendes; Soraya Rofagha; Wayne Enanoria; David S Boyer; SriniVas R Sadda; Kang Zhang Journal: Am J Ophthalmol Date: 2015-01-30 Impact factor: 5.258
Authors: Chandrakumar Balaratnasingam; Jeffrey D Messinger; Kenneth R Sloan; Lawrence A Yannuzzi; K Bailey Freund; Christine A Curcio Journal: Ophthalmology Date: 2017-01-30 Impact factor: 12.079
Authors: Juan E Grunwald; Maxwell Pistilli; Ebenezer Daniel; Gui-Shuang Ying; Wei Pan; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Maureen G Maguire; Daniel F Martin Journal: Ophthalmology Date: 2016-10-27 Impact factor: 12.079
Authors: Francis Char DeCroos; Cynthia A Toth; Sandra S Stinnett; Cynthia S Heydary; Russell Burns; Glenn J Jaffe Journal: Ophthalmology Date: 2012-08-28 Impact factor: 12.079
Authors: Ebenezer Daniel; Cynthia A Toth; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Stuart L Fine; Jiayan Huang; Gui-shuang Ying; Stephanie A Hagstrom; Katrina Winter; Maureen G Maguire Journal: Ophthalmology Date: 2013-12-04 Impact factor: 12.079
Authors: Hans E Grossniklaus; David J Wilson; Susan B Bressler; Neil M Bressler; Cynthia A Toth; W Richard Green; Päivi Miskala Journal: Am J Ophthalmol Date: 2006-01 Impact factor: 5.258
Authors: Cynthia A Toth; Vincent Tai; Maxwell Pistilli; Stephanie J Chiu; Katrina P Winter; Ebenezer Daniel; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying; Sina Farsiu; Maureen G Maguire Journal: Ophthalmol Retina Date: 2018-12-03
Authors: Thibaud Mathis; Frank G Holz; Sobha Sivaprasad; Young Hee Yoon; Nicole Eter; Lee-Jen Chen; Adrian Koh; Eduardo Cunha de Souza; Giovanni Staurenghi Journal: Eye (Lond) Date: 2022-09-14 Impact factor: 4.456
Authors: Ebenezer Daniel; Maureen G Maguire; Juan E Grunwald; Cynthia A Toth; Glenn J Jaffe; Daniel F Martin; Gui-Shuang Ying Journal: JAMA Ophthalmol Date: 2020-05-01 Impact factor: 7.389
Authors: Ebenezer Daniel; Gui-Shuang Ying; Benjamin J Kim; Cynthia A Toth; Frederick Ferris; Daniel F Martin; Juan E Grunwald; Glenn J Jaffe; Joshua L Dunaief; Wei Pan; Maureen G Maguire Journal: Ophthalmology Date: 2018-11-23 Impact factor: 12.079
Authors: Avni P Finn; Maxwell Pistilli; Vincent Tai; Ebenezer Daniel; Gui-Shuang Ying; Maureen G Maguire; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Cynthia A Toth Journal: Am J Ophthalmol Date: 2020-11-19 Impact factor: 5.258
Authors: Vuong Nguyen; Martin Puzo; Jorge Sanchez-Monroy; Pierre-Henry Gabrielle; Catherine C Garcher; Florian Baudin; Benjamin Wolff; Laurent Castelnovo; Guillaume Michel; Louise O'Toole; Daniel Barthelmes; Mark C Gillies Journal: Retina Date: 2021-07-01 Impact factor: 4.256
Authors: Limeng Wu; Sasa Vasilijic; Yao Sun; Jie Chen; Lukas D Landegger; Yanling Zhang; Wenjianlong Zhou; Jun Ren; Samuel Early; Zhenzhen Yin; William W Ho; Na Zhang; Xing Gao; Grace Y Lee; Meenal Datta; Jessica E Sagers; Alyssa Brown; Alona Muzikansky; Anat Stemmer-Rachamimov; Luo Zhang; Scott R Plotkin; Rakesh K Jain; Konstantina M Stankovic; Lei Xu Journal: Sci Transl Med Date: 2021-07-14 Impact factor: 19.319